Bluesky Facebook Reddit Email

Blood microbial DNA distinguishes liver cancer from metastatic lesions

09.17.25 | First Hospital of Jilin University

SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.


A simple blood test analyzing microbial DNA could help doctors tell apart primary liver cancer from colorectal cancer that has spread to the liver, according to a new study in eGastroenterology .

Researchers used shotgun metagenomic sequencing on blood plasma and tumor tissue samples from patients with hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC). They found that microbial DNA circulating in the blood provided stronger diagnostic signals than tissue-based profiling, revealing distinct bacterial “fingerprints” for each cancer type.

In the study, plasma samples clearly separated HCC from mCRC, while tumor tissues did not. Specific bacterial groups—including Pseudomonas aeruginosa in HCC and Acinetobacter species in mCRC—emerged as potential biomarkers.

“Blood-derived microbial DNA captures signals from across the body, not just a single lesion,” said Professor Amir Zarrinpar. “This makes it a powerful, non-invasive tool for distinguishing liver cancers that often look similar on imaging scans.”

If validated in larger studies, microbial cfDNA profiling could:

This pioneering study demonstrates that blood microbial cfDNA can distinguish hepatocellular carcinoma from metastatic colorectal cancer in the liver. By identifying distinct microbial taxa associated with each tumor type, the research lays critical groundwork for non-invasive, microbiome-based diagnostics.

Although not yet ready for clinical use, these findings point toward a future where the microbiome becomes a powerful ally in oncology, aiding in cancer detection, prognosis, and potentially guiding therapy. As sequencing costs decline and validation studies expand, microbial cfDNA may soon join the frontline of precision cancer medicine.

See the article:

Guccione C, Dantas Machado AC, Youssef F, et al . Blood microbial DNA signature differentiates hepatocellular carcinoma from metastatic lesions. eGastroenterology 2025;3:e100193. doi:10.1136/egastro-2025-100193

About eGastroenterology

eGastroenterology is a new, open-access, and open peer-reviewed BMJ Journal, which focuses on basic, clinical, translational, and evidence-based medicine research in all areas of gastroenterology (including hepatology, pancreatology, esophagology, and gastrointestinal surgery). eGastroenterology is now indexed by PubMed, Scopus, CAS, DOAJ, Dimensions, OpenAlex, ROAD , and COPE , with more to come!

For more information, please visit: egastroenterology.bmj.com and follow us on Twitter (@eGastro_BMJ).

Sign-up to Email Alerts for eGastroenterology : https://emails.bmj.com/k/Bmj/jausu/egastroenterology

eGastroenterology

10.1136/egastro-2025-100193

Blood microbial DNA signature differentiates hepatocellular carcinoma from metastatic lesions

Keywords

Article Information

Contact Information

Menghan Gao
eGastroenterology
egastro@jlu.edu.cn

How to Cite This Article

APA:
First Hospital of Jilin University. (2025, September 17). Blood microbial DNA distinguishes liver cancer from metastatic lesions. Brightsurf News. https://www.brightsurf.com/news/L3R77QZ8/blood-microbial-dna-distinguishes-liver-cancer-from-metastatic-lesions.html
MLA:
"Blood microbial DNA distinguishes liver cancer from metastatic lesions." Brightsurf News, Sep. 17 2025, https://www.brightsurf.com/news/L3R77QZ8/blood-microbial-dna-distinguishes-liver-cancer-from-metastatic-lesions.html.